Hyperfine Enrolls First Patients in PRIME Study to Accelerate Adoption of AI-Powered Portable MRI in Emergency Departments.

Hyperfine has announced the enrollment of the first patients in the PRIME study, which aims to assess the clinical and operational impact of AI-powered portable MRI across diverse patient types in ED settings. The study builds on the ACTION PMR study and will evaluate the technology's effectiveness and efficiency as a triage tool for a wide range of brain-related emergency medical conditions. The study will use Hyperfine's next-generation Swoop system powered by Optive AI software, which provides sharper anatomical detail and potentially enables greater pathology detection.

Hyperfine, Inc. (Nasdaq: HYPR), a leading health technology company, has announced the enrollment of the first patients in the PRIME (Portable Rapid Imaging for Medical Emergencies) study. This study aims to assess the clinical and operational impact of AI-powered portable MRI across diverse patient types in emergency department (ED) settings [1].

The PRIME study builds upon the ACTION PMR study, which demonstrated the utility of AI-powered portable MRI in diagnosing and managing stroke patients in ED settings. The new study will expand its scope to include a broader range of patients presenting with emergency medical conditions and evaluate the technology's effectiveness and efficiency as a triage tool [1].

The study will be conducted using Hyperfine's next-generation Swoop® system, powered by Optive AI™ software. This advanced system provides sharper anatomical detail, potentially enabling greater pathology detection. Unlike the previous ACTION PMR study, the PRIME study will use the new software's enhanced image quality, which is expected to drive greater adoption in the emergency setting [1].

Hyperfine's portable MRI technology has already shown its value in healthcare institutions by providing high-quality brain imaging at the bedside for critically ill adult and pediatric patients. The company aims to address the challenge of timely access to MRI in emergency department settings, where prolonged patient boarding is a significant issue [1].

Dr. Kevin Sheth, Professor of Neurology and Neurosurgery at Yale School of Medicine and principal investigator for the PRIME study, stated, "By evaluating the potential of portable MRI in this real-world setting, this study aims to determine if a portable MRI system can provide diagnostic imaging capabilities that can be quickly integrated into the ED workflow to improve patient care decisions in real time" [1].

Dr. Charles Wira, Associate Professor of Emergency Medicine at Yale University, added, "Given many EDs don’t have ready access to MRI, this study could alter paradigms of advanced imaging access and utilization in the ED. The Hyperfine portable MRI system could immediately provide ED clinicians and consulting physicians with critical imaging data at the point of care, helping them to make more informed, faster decisions when every second counts" [1].

Maria Sainz, President and CEO of Hyperfine, expressed her excitement about the collaboration with Yale, stating, "The Yale team has worked with portable brain MRI since the technology’s early days. Through the PRIME study, they demonstrate a bold vision for how portable MRI can accelerate triage in emergency care. The next-generation Swoop® system, powered by Optive AI™ software, provides more clinically valuable image quality that we expect will drive greater adoption in the emergency setting and help address the widespread clinical and economic challenges of ED boarding" [1].

Hyperfine is committed to advancing the role of portable MRI in emergency care of the brain, one of the sites of care where access to conventional MRI is challenging. The PRIME study represents a strategic initiative within the broader Hyperfine hospital market strategy to drive commercial growth [1].

For more information about the Swoop® system, please visit HyperfineMRI.com. For more information about the PRIME study, including enrollment details and eligibility criteria, please visit ClinicalTrials.gov.

References:
[1] https://www.stocktitan.net/news/HYPR/hyperfine-announces-first-patients-enrolled-in-prime-study-aimed-at-s997c8xkjt7m.html